GPCR Structure Therapeutics
- 48.170
- -3.470-6.72%
- 50.740
- +2.570+5.34%
Structure Therapeutics News
JPMorgan to Wager on Weight-Loss Craze With $500 Million Fund
JPMorgan Chase & Co.’s asset-management arm raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs
GLP-1 Obesity Drug Coverage Dropped by Blue Cross Michigan: Report
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Press Release: Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares SAN FRANCISCO, June 07, 2024 (GLOBE
Structure Therapeutics Is Maintained at Outperform by BMO Capital
Structure Therapeutics Is Maintained at Outperform by BMO Capital
Structure Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/07/2024 79.66% BMO Capital $83 → $100 Maintains Outperform 06/03/2024 16.78% Cantor Fitzgerald $65 → $6
Express News | Structure Therapeutics Inc : BMO Raises Target Price to $100 From $83
Structure Therapeutics Vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?
Structure Therapeutics Prices Upsized $476 Million Stock Offering
Structure Therapeutics (GPCR) said late Wednesday it has priced an upsized underwritten public offering of about 9.1 million American depositary shares at $52.50 per ADS. Gross proceeds from the offer
Reported Earlier, Structure Therapeutics Prices Upsized $476M Public Offering 9,066,972 American Depositary Shares At $52.50/ADS
Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announc
Express News | Structure Therapeutics Inc - Pricing of Its Upsized Underwritten Public Offering of 9.1 Mln American Depositary Shares at $52.50 per Ads
Structure Therapeutics' 9.1 Million-ADS Offering Prices at $52.50 an ADS >GPCR
Structure Therapeutics' 9.1 Million-ADS Offering Prices at $52.50 an ADS >GPCR
Express News | Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
Qiming's Nisa Leung Made the 2024 Forbes Midas List
The 2024 Forbes Midas List, a distinguished industry list of the world's best venture capital investors, has been unveiled. Nisa Leung, Managing...
Express News | Structure Therapeutics Inc : Leerink Partners Raises Target Price to $93 From $58
Shuodi Biotechnology's weight loss medicine can help patients lose nearly 7% of their weight in a year, causing the stock price to soar over 80%.
Chronic disease biopharmaceutical company Structure Therapeutics, formerly known as Shuodi Biotech, is also trying to compete with Eli Lilly and Co. and Novo Nordisk in the weight loss drug market. On June 3, according to media reports, the company is developing an alternative to injectable weight loss drugs - oral weight loss drugs, and Structure Therapeutics announced its preliminary test results for the oral weight loss drug on Monday. The results showed that in the mid-term clinical trial of Structure drug GSBR-1290, patients lost an average of over 6% of their body weight in 12 weeks. In another early study, the drug
Express News | Structure Therapeutics Files Registration Statement For Proposed Public Offering Of 8M ADSs
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
Analysis
Price Target
No Data
